ReviewVirulence2025
Immunoevasion strategies for African swine fever virus: Modulation of antigen presentation pathways.
Review in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- African swine fever virus pM448R protein promotes STUB1-mediated ubiquitin-proteasome degradation of IRF1 to attenuate type III interferon induction.Journal of virology · 2026Article
- Host-pathogen interactions in African swine fever: From viral entry to systemic disease progression.Cell insight · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus (ASFV), a highly lethal pathogen, poses a catastrophic threat to global pork production. While some commercial vaccines exist, their availability remains regional limitations. This review investigates the mechanistic interplay between ASFV and antigen-presenting cells (APCs), with a particular focus on viral evasion strategies that disrupt antigen presentation pathways. Although current understanding of ASFV immunology has largely focused on monocyte/macrophage infection, we provide a systematic analysis of ASFV-mediated immunosuppression across various APCs, including dendritic cells (DCs), B lymphocytes, and γδ T cells, and compare these mechanisms with those employed by other viral pathogens. Key objectives include: (1) synthesizing ASFV-induced dysregulation of antigen presentation, (2) identifying critical gaps in APC-virus interactions, and (3) guiding vaccine development priorities. By highlighting understudied DC-ASFV interplay and potential molecular targets, this work provides a strategic framework for next-generation vaccine design based on host-pathogen conflict at the antigen presentation interface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.